Drug maker AstraZeneca has agreed to pay $520 million to settle whistleblower lawsuits filed in federal court in Philadelphia that accused the company of engaging in illegal tactics — including kickbacks to doctors — to promote so-called “off-label” uses for one of its drugs.
The drug, Seroquel, is an anti-psychotic that was approved by the Food and Drug Administration only for narrow uses, such as combating schizophrenia or acute manic episodes in those with bipolar disorder. But prosecutors said AstraZeneca set out to market the drug directly to doctors for a wider range of ailments including Alzheimer’s disease, anger management, depression and sleeplessness.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
